Financeability tests and their role in price regulation - IPART - NSW ...
Financeability tests and their role in price regulation - IPART - NSW ...
Financeability tests and their role in price regulation - IPART - NSW ...
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
5 How should <strong>IPART</strong> respond when a bus<strong>in</strong>ess fails the<br />
f<strong>in</strong>anceability test?<br />
5 How should <strong>IPART</strong> respond when a bus<strong>in</strong>ess fails the<br />
f<strong>in</strong>anceability test?<br />
Where our f<strong>in</strong>anceability test <strong>in</strong>dicates that a regulated bus<strong>in</strong>ess’s projected credit<br />
rat<strong>in</strong>g will fall below <strong>in</strong>vestment grade dur<strong>in</strong>g the determ<strong>in</strong>ation period, we have to<br />
decide how to respond. In particular, we need to assess whether the potential<br />
f<strong>in</strong>ancial viability issues are best managed by the bus<strong>in</strong>ess or its shareholders, or<br />
whether we should adjust our build<strong>in</strong>g block model <strong>in</strong>puts (<strong>and</strong> thus the proposed<br />
<strong>price</strong>s) to improve the bus<strong>in</strong>ess’s cash flows <strong>and</strong> thus prevent the deterioration <strong>in</strong> its<br />
expected credit rat<strong>in</strong>g.<br />
The sections below discuss a range of issues related to this question that we will<br />
consider as part of this review. These issues <strong>in</strong>clude:<br />
� whether we should allow for equity rais<strong>in</strong>gs <strong>in</strong> sett<strong>in</strong>g <strong>price</strong>s or suggest equity<br />
<strong>in</strong>jections to ensure short-term f<strong>in</strong>ancial viability?<br />
� the circumstances, if any, should <strong>IPART</strong> make adjustments to <strong>price</strong>s to address<br />
f<strong>in</strong>anceability issues?<br />
� the options for mak<strong>in</strong>g such adjustments are available?<br />
� whether any such adjustments be NPV neutral?<br />
� the regulatory precedents for mak<strong>in</strong>g such adjustments?<br />
5.1 Should <strong>IPART</strong> allow for equity rais<strong>in</strong>gs or m<strong>and</strong>ate equity <strong>in</strong>jections<br />
to ensure short-term f<strong>in</strong>ancial viability?<br />
One of the pr<strong>in</strong>ciples of <strong>in</strong>centive <strong>regulation</strong> is that it should seek to replicate the<br />
pressures of a competitive market. In such a market, the participants are <strong>price</strong>-takers<br />
<strong>and</strong> cannot set <strong>price</strong>s to directly match <strong>their</strong> specific f<strong>in</strong>anc<strong>in</strong>g requirements –<br />
whether these are due to the asset cycle stage they are <strong>in</strong>, <strong>their</strong> level of efficiency or<br />
<strong>their</strong> f<strong>in</strong>anc<strong>in</strong>g strategies. This pr<strong>in</strong>ciple suggests that, <strong>in</strong> the first <strong>in</strong>stance, the<br />
responsibility for manag<strong>in</strong>g short- to medium-term f<strong>in</strong>anceability issues should rest<br />
with the bus<strong>in</strong>ess. This is also consistent with the pr<strong>in</strong>ciple of allocat<strong>in</strong>g risk to those<br />
who can best manage it (<strong>in</strong> this case, the management of the bus<strong>in</strong>ess rather than its<br />
customers).<br />
As section 3.3 noted, there are a range of options available to bus<strong>in</strong>esses <strong>and</strong> <strong>their</strong><br />
shareholders to manage <strong>their</strong> f<strong>in</strong>anceability. One of these options is equity <strong>in</strong>jections.<br />
These may take the form of direct equity <strong>in</strong>jections from exist<strong>in</strong>g or new shareholders<br />
or through reta<strong>in</strong>ed earn<strong>in</strong>gs. If reta<strong>in</strong>ed earn<strong>in</strong>g are not sufficient to cover the<br />
<strong>F<strong>in</strong>anceability</strong> <strong>tests</strong> <strong>and</strong> <strong>their</strong> <strong>role</strong> <strong>in</strong> <strong>price</strong> <strong>regulation</strong> <strong>IPART</strong> 25